سعر ستاتيوريك 80مجم 30 قرص 2024

Staturic 80 mg (Mash Premiere, Egypt), 30 film-coated tablets: febuxostat 80 mg, a xanthine oxidase inhibitor used to lower serum uric acid in gout.

• Chronic management of hyperuricaemia in adults with gout who have an inadequate response to, are intolerant of, or are not suitable for a maximally titrated dose of allopurinol; not recommended for asymptomatic hyperuricaemiaPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including history or presence of tophus and/or gouty arthritis), in adultsPopulation: AdultsEuropean Medicines Agency (EMA)

• Adverse reactions in at least 1% of patients in controlled studies: liver function abnormalities, nausea, arthralgia and rash.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Contraindicated in patients being treated with azathioprine or mercaptopurine.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to the active substance or to any of the excipients.International label, same formulation · European Medicines Agency (EMA)

• In patients with pre-existing major cardiovascular disease (e.g. myocardial infarction, stroke, unstable angina) more fatal cardiovascular events were seen with febuxostat than allopurinol in development and in the CARES study, although the later FAST study showed non-inferiority; treatment of such patients should be cautious.International label, same formulation · European Medicines Agency (EMA)
• Boxed warning: gout patients with established cardiovascular disease had a higher rate of CV death with ULORIC than allopurinol (CARES); use only in patients with inadequate response to or intolerance of allopurinol, or for whom allopurinol is not advisable.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Gout flares frequently increase after initiation; NSAID or colchicine prophylaxis is recommended (up to 6 months) and febuxostat need not be stopped during a flare.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Azathioprine / mercaptopurineXanthine oxidase inhibition markedly increases 6-mercaptopurine exposure (clearance reduced about 83%); concomitant use contraindicated in the US label.DailyMed (U.S. National Library of Medicine)
• TheophyllineFebuxostat altered theophylline metabolism (about 400-fold increase in urinary 1-methylxanthine); use with caution.DailyMed (U.S. National Library of Medicine)
• Colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin, desipramineNo clinically significant interactions; may be used concomitantly.DailyMed (U.S. National Library of Medicine)

• Limited human data are insufficient to inform a drug-associated risk; no adverse developmental effects in rats and rabbits at exposures up to about 40 and 51 times the maximum recommended human dose.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Data on a very limited number of exposed pregnancies have not shown adverse effects; potential human risk is unknown and febuxostat should not be used during pregnancy.General active-ingredient information · European Medicines Agency (EMA)
• No data on presence in human milk or effects on the breastfed infant; febuxostat is present in rat milk. Weigh benefits of breastfeeding against maternal need.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Febuxostat: 2-arylthiazole derivative that lowers serum uric acid by potent, selective, non-purine inhibition of xanthine oxidase (oxidised and reduced forms), which catalyses hypoxanthine to xanthine to uric acid (EU SmPC).